Automation in Peptide-Oligonucleotide Conjugate Synthesis

Introduction:

Automation in Peptide-Oligonucleotide Conjugate Synthesis is becoming increasingly important as researchers seek more reproducible and scalable ways to manufacture complex molecules that combine peptide and oligonucleotide components. Peptide-oligonucleotide conjugates (POCs) combine the biological activity of an oligonucleotide with peptide-mediated delivery or cellular targeting, addressing limitations often associated with uptake and biodistribution in peptide-oligonucleotide conjugate drug delivery applications, and increasingly play a role in receptor-targeted conjugate design.

Unlike conventional small molecules, POCs contain two chemically different biomolecular components. Their synthesis can involve multiple protecting groups, orthogonal reaction conditions, sensitive functional groups, and purification challenges. Published literature describes both stepwise solid-phase synthesis and post-synthetic conjugation approaches, spanning several distinct types of peptide-oligonucleotide conjugates, each with different mechanisms of action.

Automation provides an opportunity to standardize these operations while generating a more controlled and traceable workflow. However, automation does not eliminate the need for chemistry expertise — the automated platform must be designed around the reaction chemistry, analytical controls, and quality attributes of the specific conjugate, informed early by preclinical services for peptide-oligonucleotide conjugates.

Summary:

• Automation in Peptide-Oligonucleotide Conjugate Synthesis combines automated solid-phase peptide synthesis (SPPS), automated oligonucleotide synthesis, and controlled conjugation workflows to reduce manual variability.
• Automation improves reaction consistency, reagent delivery accuracy, cycle-to-cycle reproducibility, traceability, and throughput compared with manual workflows.
• Peptide-oligonucleotide conjugates (POCs) are increasingly investigated for targeted delivery, cellular uptake, gene modulation, and nucleic-acid therapeutic applications.
• The two major synthetic strategies are stepwise synthesis on a common solid support and post-synthetic conjugation performed in solution or on a solid phase.
• Automated workflows must control critical variables such as sequence accuracy, coupling efficiency, protecting-group chemistry, conjugation efficiency, reaction time, reagent quality, and purification.
• Analytical characterization using LC-MS, HRMS, RP-HPLC, ion-exchange chromatography, and NMR where appropriate is essential for confirming identity, purity, and impurity profiles.
• A robust automation strategy integrates synthesis, process monitoring, purification, analytical testing, electronic records, and quality controls — not just automated reagent addition.
• For pharmaceutical development, automation should be supported by method validation/qualification, system suitability, data integrity controls, and documented process parameters.

1: What Is Automation in Peptide-Oligonucleotide Conjugate Synthesis?

Automation in Peptide-Oligonucleotide Conjugate Synthesis means using programmable synthesis platforms and controlled process workflows to execute repetitive chemical operations with limited manual intervention. These operations can include reagent dispensing, coupling, washing, deprotection, reaction timing, cleavage, and — in suitable platforms — transfer between synthesis and purification steps, following established POC synthesis and characterization workflows.

A typical automated workflow may include:

• Sequence and synthesis-plan configuration
• Resin or solid-support preparation
• Automated peptide or oligonucleotide chain assembly
• Controlled reagent dispensing
• Coupling and reaction cycles
• Washing and deprotection
• Installation of a linker or reactive handle
• Peptide-oligonucleotide conjugation
• Cleavage and global deprotection
• Purification
• LC-MS/HRMS and chromatographic characterization
• Final data review and documentation

The precise sequence depends on whether the POC is produced by single-support stepwise synthesis or by synthesizing the peptide and oligonucleotide separately and subsequently conjugating them — a choice covered in more depth in our overview of peptide-oligonucleotide conjugate synthesis methods.

2: Why Is Automation Important for Peptide-Oligonucleotide Conjugates?

Automation is valuable because POC synthesis contains many repetitive operations where small differences in reagent volume, reaction time, temperature, mixing, or washing can influence product quality. Manual synthesis can introduce operator-to-operator variability, particularly when a project requires multiple conjugates, sequence variants, or repeated batches, and this variability becomes a larger risk once a program moves into GMP manufacturing of peptide-oligonucleotide conjugates.

This becomes particularly important when synthesizing libraries of peptide sequences, oligonucleotide sequences, linker variants, or conjugation chemistries destined for peptide-oligonucleotide conjugate manufacturing at increasing scale.

3: Major Workflow Strategies for Automated POC Synthesis

The two broad approaches to automated POC synthesis are integrated stepwise synthesis and post-synthetic conjugation, and the optimal strategy depends on the molecular architecture and compatibility of the peptide, oligonucleotide, linker, and reaction conditions.

Automated Stepwise Solid-Phase Synthesis

In an integrated strategy, components are assembled sequentially on a suitable solid support, and the synthesis platform executes repeated cycles of coupling, washing, and deprotection. This approach can provide:

• Reduced intermediate handling
• Consistent reaction cycles
• A potentially simplified workflow
• Reduced manual transfer steps
• Convenient incorporation of linkers or terminal functional groups

However, chemical compatibility becomes a major consideration. Peptide and oligonucleotide synthesis use different chemistries, and conditions suitable for one component may not be optimal for the other — a factor closely tied to peptide-oligonucleotide conjugate linker chemistry selection.

Automated Post-Synthetic Conjugation

An alternative is to synthesize the peptide and oligonucleotide independently and then join them using a selective conjugation reaction. Potential advantages include:

• Independent optimization of peptide synthesis
• Independent optimization of oligonucleotide synthesis
• Greater flexibility in selecting conjugation chemistry
• Easier troubleshooting of individual components
• Potentially broader structural compatibility

Recent research has demonstrated peptide-oligonucleotide conjugation using catalytic approaches both on-column and in aqueous solution, illustrating the continued development of conjugation methodologies and reflecting broader questions programs face when comparing peptide-conjugate vs. antibody-oligonucleotide conjugate delivery strategies.

4: Which Chemistries Can Be Integrated Into Automated POC Workflows?

The appropriate conjugation chemistry depends on the functional groups available on the peptide and oligonucleotide and the required stability of the final linkage. Reported approaches include amide coupling, thiol-based reactions, oxime or hydrazone-type linkages, and click-chemistry strategies.

Common considerations include:

• Functional-group selectivity
• Reaction conversion
• Compatibility with protecting groups
• Stability of the oligonucleotide
• Stability of the peptide
• Linker stability
• Requirement for metal catalysts
• Removal of residual reagents
• Compatibility with downstream purification

Click chemistry, for example, has been investigated for POC preparation, including thiol-maleimide and copper-catalyzed azide-alkyne cycloaddition approaches. Automation should be developed around the chemistry rather than simply transferring a manual protocol onto an automated instrument, and linker choice directly affects downstream peptide-oligonucleotide conjugate stability.

5: Critical Process Parameters in Automated POC Synthesis

The most important process parameters are those that directly affect coupling efficiency, sequence integrity, conjugation efficiency, impurity formation, and final product recovery.

Key parameters can include:

• Reagent concentration and reagent excess
• Dispensing accuracy
• Coupling time and reaction temperature
• Mixing efficiency
• Deprotection conditions
• Washing cycles
• Solid-support loading
• Linker chemistry
• Conjugation stoichiometry
• pH and solvent composition
• Reaction atmosphere where relevant
• Cleavage conditions
• Intermediate hold times

A scientifically sound automation program should identify which parameters are critical for the particular POC and establish suitable operating ranges through development studies feeding into a formal CMC services for peptide-oligonucleotide conjugates package.

6: What Analytical Support Does Automated POC Synthesis Require?

Automation improves synthesis consistency, but analytical characterization determines whether the resulting POC has the expected identity, purity, and molecular composition — automation controls execution, it does not confirm the product.

LC-MS and HRMS. Mass spectrometry characterization of peptide-oligonucleotide conjugates can provide molecular-weight information and help identify full-length POC, truncated sequences, deletion products, incomplete conjugates, over-conjugated species, linker-related products, oxidation products, and other mass-variable impurities. High-resolution mass spectrometry can be particularly useful when closely related species need to be differentiated.

RP-HPLC. HPLC purification services for peptide-oligonucleotide conjugates help assess chromatographic purity and resolve related species. For oligonucleotide-related materials, chromatographic conditions may require careful optimization because of their size, charge, polarity, and chemical modifications.

Ion-exchange chromatography. This approach provides complementary separation based on charge differences and can be useful for oligonucleotide-containing products and their related impurities.

NMR. NMR can provide complementary structural information where sample quantity and molecular size permit.

An orthogonal strategy that avoids depending on a single technique is central to reliable peptide-oligonucleotide conjugate analysis:

USP materials also demonstrate the use of complementary RP-HPLC, ³¹P NMR, and MS approaches in the characterization of DNA phosphoramidite materials, illustrating the value of orthogonal analytical techniques for nucleic-acid-related chemistry, and this same orthogonal thinking underpins routine QC testing for peptide-oligonucleotide conjugates and impurity profiling for peptide-oligonucleotide conjugates, as well as bioanalytical method development for POC therapeutics once a conjugate advances toward in vivo studies.

7: How Automation Improves Reproducibility and Data Quality

The major quality advantage of automation is the ability to execute predefined operations consistently while recording process information for review and troubleshooting. A well-designed automated workflow can capture:

• Instrument identification
• Method or synthesis program
• Reagent identity and lot information
• Dispensing sequence
• Reaction duration
• Operator information
• Date and time
• Deviations or alarms
• Final batch information

This information helps establish traceability from synthesis conditions to analytical results, which is directly relevant to specification-setting for peptide-oligonucleotide conjugates and to building the data package required for peptide-oligonucleotide conjugates in IND submissions.

Importantly, automation should not be considered a substitute for data integrity controls. Electronic records, user access, audit trails, method version control, and appropriate review processes remain important when automated systems are used in regulated development or manufacturing environments.

8: Common Challenges in Automating Peptide-Oligonucleotide Conjugate Synthesis

Automation reduces repetitive manual work, but POC synthesis remains technically challenging because the final molecule combines two chemically complex components — a reality explored further in challenges in peptide-oligonucleotide conjugates.

• Chemical incompatibility — peptide and oligonucleotide chemistries may require different conditions
• Sequence-dependent behavior — certain sequences can be more difficult to synthesize or purify
• Incomplete coupling — small inefficiencies repeated over many synthesis cycles can generate significant related impurities
• Conjugation selectivity — reactive groups must be controlled to minimize unwanted side reactions
• Purification complexity — POCs can behave very differently from either starting component
• Analytical complexity — closely related impurities may require high-resolution analytical techniques
• Scale-up — conditions that perform well at small scale may require re-optimization at larger scale, a topic covered in our guide to scale-up of peptide-oligonucleotide conjugates
• Automation transfer — an automated method must reproduce the chemically relevant aspects of the original development procedure

Published research has specifically recognized purification as a significant challenge for some POCs, particularly structurally complex or self-assembling conjugates, and unresolved impurities can influence peptide-oligonucleotide conjugate degradation pathways over shelf life, which in turn shapes handling and storage requirements for peptide-oligonucleotide conjugates.

9: Best Practices for Automation in Peptide-Oligonucleotide Conjugate Synthesis

The best automation strategy begins with a chemically understood and analytically controlled process, followed by systematic automation of repeatable operations.

1. Define the target product and critical quality attributes before automation.
2. Map each manual synthesis operation before programming the automated workflow.
3. Verify reagent compatibility with tubing, valves, reservoirs, and other instrument components.
4. Establish appropriate system suitability criteria.
5. Use qualified or appropriately characterized reagents and starting materials.
6. Include controls for dispensing and reaction timing.
7. Build error detection into the workflow where possible.
8. Maintain version-controlled synthesis programs.
9. Use orthogonal analytical methods to confirm product identity and purity.
10. Establish impurity profiles during development rather than relying only on final purity.
11. Document deviations and investigate unexpected analytical profiles.
12. Confirm that automated processes remain reproducible after scale or sequence changes.

10: How ResolveMass Can Support POC Analytical Development

For complex peptide-oligonucleotide projects, analytical development should connect synthesis decisions with measurable molecular attributes and impurity profiles. This is where specialized analytical expertise can add value during research, development, and characterization programs, including studies feeding into peptide-oligonucleotide conjugate toxicology studies, pharmacokinetics assessments, and immunogenicity evaluation — including specialized immunogenicity risk assessment approaches for gene-modulating conjugates such as those used in gene-silencing applications.

A CRO-led analytical strategy may involve:

• LC-MS-based molecular characterization
• High-resolution mass spectrometry
• Peptide sequence and modification characterization
• Oligonucleotide impurity profiling
• Chromatographic method development
• Conjugation confirmation
• Structural characterization
• Comparative analytical assessment
• Method optimization for complex biomolecular products

For development programs, the analytical strategy should be tailored to the molecule rather than applying a generic test panel. The objective is to establish scientifically defensible evidence that the expected POC was produced and to understand the related substances generated during synthesis, informed from the earliest preclinical services stage through IND-enabling work.

Conclusion:

Automation in Peptide-Oligonucleotide Conjugate Synthesis can transform a highly repetitive and technically demanding workflow into a more controlled, reproducible, and traceable process — but automation is most effective when supported by strong chemistry and analytical characterization. The literature supports multiple routes for producing POCs, including stepwise solid-phase synthesis and post-synthetic conjugation, and emerging conjugation strategies continue to expand the range of structures that can be prepared.

For pharmaceutical and biotechnology development programs, the most effective approach is therefore not simply to automate synthesis. It is to establish an integrated workflow connecting chemical synthesis → automated process control → purification → LC-MS/HRMS characterization → impurity profiling → documented quality assessment. As peptide and oligonucleotide therapeutics continue to evolve, this combination of automation and advanced analytical science helps development teams generate more consistent material, accelerate molecular optimization, and build stronger analytical evidence for complex conjugate programs.

Frequently Asked Questions:

Reference

• Venkatesan N, Kim BH. Peptide conjugates of oligonucleotides: synthesis and applications. Chemical reviews. 2006 Sep 13;106(9):3712-61.https://pubs.acs.org/doi/full/10.1021/cr0502448
• Taskova M, Mantsiou A, Astakhova K. Synthetic nucleic acid analogues in gene therapy: an update for peptide–oligonucleotide conjugates. ChemBioChem. 2017 Sep 5;18(17):1671-82.https://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cbic.201700229
• Lu K, Duan QP, Ma L, Zhao DX. Chemical strategies for the synthesis of peptide− oligonucleotide conjugates. Bioconjugate chemistry. 2010 Feb 17;21(2):187-202.https://pubs.acs.org/doi/abs/10.1021/bc900158s
• Zubin EM, Romanova EA, Tat’yana SO. Modern methods for the synthesis of peptide–oligonucleotide conjugates. Russian chemical reviews. 2002 Mar 31;71(3):239-64.https://iopscience.iop.org/article/10.1070/RC2002v071n03ABEH000707/meta
• Tung CH, Stein S. Preparation and applications of peptide− oligonucleotide conjugates. Bioconjugate Chemistry. 2000 Sep 18;11(5):605-18.https://pubs.acs.org/bcches/article-abstract/11/5/605/3453926

About the Author

Priyal Darji